智通财经APP讯,乐普生物-B(02157)发布公告,于2025年11月28日,本公司与乐普医疗订立CDMO服务框架协议,本公司及/或其附属公司同意向乐普医疗及/或其附属公司提供CDMO技术服务。
考虑到本集团为满足自身临床试验及商业化而对药物生产的需求之外,本集团可在适当的商机出现时更有效利用富余产能。董事认为,订立CDMO服务框架协议将能更有效利用本集团的富余产能,可为本集团整体产生补充现金流量。
智通财经APP讯,乐普生物-B(02157)发布公告,于2025年11月28日,本公司与乐普医疗订立CDMO服务框架协议,本公司及/或其附属公司同意向乐普医疗及/或其附属公司提供CDMO技术服务。
考虑到本集团为满足自身临床试验及商业化而对药物生产的需求之外,本集团可在适当的商机出现时更有效利用富余产能。董事认为,订立CDMO服务框架协议将能更有效利用本集团的富余产能,可为本集团整体产生补充现金流量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.